Cybin Announces Additional U.S. Patent Supporting Its CYB003 Breakthrough Therapy Program In Phase 3 Development For Major Depressive Disorder

RefinitivMeno di 1 minuto di lettura

Cybin Inc CYBN:

CYBIN ANNOUNCES ADDITIONAL U.S. PATENT SUPPORTING ITS CYB003 BREAKTHROUGH THERAPY PROGRAM IN PHASE 3 DEVELOPMENT FOR MAJOR DEPRESSIVE DISORDER

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Accedi o crea un account gratuito per leggere queste notizie